We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




R&D Partnership Initiated to Reduce Development Time for New Drugs

By LabMedica International staff writers
Posted on 09 Dec 2014
Print article
nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer Ingelheim’s imaging diagnostics. The first joint projects have already begun and many more are being planned.


After several years of close collaboration between Boehringer Ingelheim and nanoPET Pharma, there now exists a framework contract between the two companies. This contract has a long-term perspective and will include various joint projects. “This cooperation model is based on a true partnership,” explained Dr. Andreas Briel, CEO of nanoPET Pharma. “Research, development, and marketing of therapeutic substances will be led by Boehringer Ingelheim; preclinical diagnostics will be managed by nanoPET. This ensures that the business fields remain strictly separate and that both partners benefit.”

The aim of the projects is to support Boehringer Ingelheim in the early identification of suitable drug candidates, to accelerate the process and, at the same time, to lessen the preclinical phase through the use of optimized imaging technology. Customized contrast agents enable the implementation of high-resolution in vivo monitoring techniques with resolutions down to the micrometer range in preclinical studies. Of importance to note is that such methods also enable a reduction in the number of laboratory animals. Of course, during the past several years, regulatory authorities constantly demand proof of the use of sophisticated imaging modalities in drug development, during the preparation of approval documentation.

Dr. Andreas Briel concluded, “We provide what any pharmaceutical development company needs during the preclinical phase: a clear and significant image which protects the living organism. Our services support the 3R-concept of “replace, reduce, and refine.”

Within this collaboration, nanoPET Pharma scientists will also study, in the medium-term, opportunities for the implementation of imaging methods as companion diagnostics in human medicine.

nanoPET Pharma explores and develops various diagnostic imaging agents. A section of the company’s core business is the proprietary product line with 21 substances, which are applied in magnetic resonance imaging (MRI), computed tomography (CT), optical imaging, and ultrasound in preclinical research worldwide. Furthermore, nanoPET Pharma develops specialized contrast agents for implementation in pharmaceutical research. Moreover, nanoPET focusses on positron-emitting inorganic nanoparticles for molecular and cell-specific positron emission tomography (PET) imaging, a diagnostic tool that allows imaging of the human body. The market potential of this technology is estimated at several hundred million Euros.

Related Links:
nanoPET Pharma
Boehringer Ingelheim


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.